Delivery Order 36F79718D0528-36C24920N0470
Award Date 5/5/20
Potential Completion Date 5/6/20
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bartlett, TN 38134, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 12 to Acorda Therapeutics, Inc., a biotechnology company that develops and commercializes neurological therapies. The $493,607.04 firm fixed-price delivery order is for the supply of Levodopa 42mg inhalers, which are used to treat Parkinson's disease symptoms. This delivery order is issued under Acorda Therapeutics' Federal Supply Schedule (FSS)...
- Lundbeck LLC was awarded a $20,381.20 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9. The firm fixed price order is for the delivery of DROXIDOPA 300MG CAPSULES to a location in Nashville, Tennessee, with performance to be completed by March 20, 2020. No set-aside designation was applied to this order placed under GSA Schedule contract FSS-61-IB. The Department...
- Lundbeck LLC was awarded a $20,381.18 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9. The firm fixed price order is for the delivery of DROXIDOPA 300MG to the place of performance in Nashville, Tennessee, with a completion date of June 18, 2020. The award was made without a set-aside designation off the GSA Schedule master contract vehicle. The Department of...
- This is a federal contract award to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological disorders. The contract, awarded by the U.S. Department of Veterans Affairs (VA), is a delivery order under Acorda's Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million. The specific contract award is for $339,032.88 and is for the supply of Levodopa 42mg inhalation capsules, a medication used to treat Parkinson's disease symptoms. This contract is...
- On September 9, 2020, the Department of Veterans Affairs, Veterans Integrated Service Network 12, awarded a $10,034.63 delivery order to Otsuka America Pharmaceutical Inc. for tolvaptan dose packs to be delivered to Pittsburgh, Pennsylvania. This firm-fixed-price contract was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries an ultimate completion date of October 10, 2020. The award utilized no set-aside designation, reflecting the vendor's status as an...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 (VA - VHA) awarded a $529,876.80 delivery order contract to Acorda Therapeutics, Inc. under the company's Pharmaceuticals and Drugs (FSS-61-IB) master agreement on the General Services Administration (GSA) Federal Supply Schedule. The contract calls for Acorda Therapeutics, Inc. to provide PHARMACEUTICAL - LEVODOPA 42MG FOR HINES CMOP to the VA medical center in Pearl River, New York from...
- On July 1, 2020, the Department of Veterans Affairs, specifically Veterans Integrated Service Network (VISN) 22, awarded a delivery order valued at $235,049.49 to Otsuka America Pharmaceutical Inc. for the provision of Jynarque (tolvaptan), a specialty pharmaceutical medication used to treat autosomal dominant polycystic kidney disease and hyponatremia. The contract, which was completed by August 12, 2021, was issued under a firm fixed-price arrangement with no set-aside designation and was...
- Otsuka America Pharmaceutical Inc., a specialty pharmaceutical manufacturer headquartered in Rockville, Maryland, received a delivery order award from the Department of Veterans Affairs Veterans Integrated Service Network 5 on January 14, 2025, for the supply of Jynarque (tolvaptan) 90mg-30mg tablets. This firm-fixed-price delivery order, valued at $13,168.39, is expected to be completed by January 17, 2025, and will be delivered to VA facilities in Pittsburgh, Pennsylvania. The award does not...
- The Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a $12,559.90 firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for Jynarque 90mg-30mg on March 8, 2024, with an ultimate completion date of March 15, 2024. Jynarque (tolvaptan) is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. This delivery order was issued without a set-aside designation and is issued under the...
- On June 22, 2021, the Department of Veterans Affairs, Veterans Integrated Service Network 6, awarded a firm fixed-price delivery order to Otsuka America Pharmaceutical Inc. for $10,303.55 for the supply of Jynarque 15mg/45mg tablets. Jynarque (tolvaptan) is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The delivery order is set to be completed by July 1, 2021, with performance occurring in Pittsburgh,...